Research

Hormonal

Treatment with PPAR-gamma agonists (thiazolidinediones) increases circulating adiponectin levels, which may mediate their insulin-sensitizing effects.

Thiazolidinediones, a class of diabetes medications, work in part by increasing levels of the hormone adiponectin. This increase in adiponectin helps improve insulin sensitivity. If you are considering medication for diabetes, discuss with your doctor how these drugs might affect your hormonal balance and metabolic health.

GoodSupportsHIGH confidence
The treatment with PPAR-gamma receptor agonists, thiazolidine-diones, increased circulating adiponectin levels under both experimental conditions in rodent models of obesity (Combs et al. 2002) and in patients with obesity/type 2 diabetes (Maeda et al. 2001), while metformin or PPAR-alpha agonists had no effect. It thus seems that part of the insulin-sensitizing effect of thiazolidinediones might be mediated by an increase of adiponectin levels.
Martin Haluzı́k et al. · Physiological Research · 2004

Why this rating

Supported by studies in both rodent models and human patients with obesity/type 2 diabetes.

Source

Adiponectin and its role in the obesity-induced insulin resistance and related complications.

Martin Haluzı́k et al. · Physiological Research · 2004

DOI 10.33549/physiolres.930479

narrative_reviewCited 192×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →